Simultaneous Determination of Ebastine and Its Active Metabolite (Carebastine) in Human Plasma Using LC–MS–MS
- 91 Downloads
A sensitive and rapid LC–MS–MS method was developed for the simultaneous determination of ebastine and carebastine in human plasma. Solid-phase extraction was used to isolate the compounds from the biological matrix followed by separation on a Symmetry C18 column under isocratic conditions. The mobile phase was 10 mM ammonium formate in water/acetonitrile (40:60, v/v). Detection was carried out using a triple-quadrupole mass spectrometer in positive electrospray ionization and multiple reaction monitoring mode. The method was fully validated over the concentration range of 0.1–10 ng mL−1 for ebastine and 0.2–200 ng mL−1 for carebastine in human plasma, respectively. The lower limit of quantification (LLOQ) was 0.1 ng mL−1 for ebastine and 0.2 ng mL−1 for carebastine. For ebastine and carebastine inter- and intra-day precision (CV%) and accuracy values were all within ±15% and 85–115%, respectively. The extraction recovery was on average 60.0% for ebastine and 60.3% for carebastine.
KeywordsColumn liquid chromatography–tandem mass spectrometry Ebastine Carebastine Human plasma
- 5.US Department of Health and Human Services Food and Drug Administration, Guidance for Industry: Bioanalytical Method validation, US Department of Health and Human Services: Rockville, MD, 2001. Website: http://www.fda.gov/cder/guidance/index.htm
- 6.State food and drug administration, The Guidance of bioavailability and bioequivalence study technique for chemistry drug in human (No. [H]GCL2-1). 2005. Website: http://www.sda.gov.cn/gsz05106/08.pdf